Get the Stockscreener App
24.22
2.15%
0.51
Seaport Therapeutics Inc stock is traded at $24.22, with a volume of 121.15K.
It is up +2.15% in the last 24 hours and up +18.49% over the past month.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
See More
Previous Close:
$23.71
Open:
$23.79
24h Volume:
121.15K
Relative Volume:
0.64
Market Cap:
$1.30B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-33.65
EPS:
-0.7198
Net Cash Flow:
-
1W Performance:
+2.54%
1M Performance:
+18.49%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.39
$24.33
1-Week Range:
$22.80
$24.64
52-Week Range:
$14.85
$24.64
Seaport Therapeutics Inc Stock (SPTX) Company Profile
Name
Seaport Therapeutics Inc
Sector
Industry
Phone
617-807-4062
Address
6 TIDE STREET, BOSTON
Compare SPTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPTX
Seaport Therapeutics Inc
|
24.22 | 1.27B | 0 | 0 | 0 | -0.7198 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Seaport Therapeutics Inc Stock (SPTX) Latest News
PureTech Health (SPTX holder) discloses 31.2% Seaport Therapeutics stake - Stock Titan
Top Seaport Therapeutics (SPTX) Competitors 2026 - MarketBeat
Seaport Therapeutics (SPTX) Stock Chart and Price History 2026 - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week HighHere's What Happened - MarketBeat
Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation - Seeking Alpha
Seaport Therapeutics, Inc. Common Stock (NASDAQ: SPTX) Stock Price, News & Analysis - kalkine.ca
Seaport Therapeutics (SPTX) Institutional Ownership 2026 - MarketBeat
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Seaport Therapeutics Inc. (SPTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week HighTime to Buy? - MarketBeat
HC Wainwright Has Negative Outlook for SPTX FY2026 Earnings - MarketBeat
Analysts’ Top NA Picks: Ceribell, Inc. (CBLL), Ethos Technologies Inc. Class A (LIFE) - The Globe and Mail
Seaport Therapeutics (SPTX): Daphne Zohar discloses 5.23M-share, 9.1% beneficial stake - Stock Titan
Seaport Therapeutics (SPTX) insider Steven M. Paul reports 6.3% stake - stocktitan.net
Seaport Therapeutics Reaffirmed at Buy as Clinical Pipeline Advances and $50 Price Target Remains Unchanged - TipRanks
Citi Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
H.C. Wainwright Maintains Seaport Therapeutics(SPTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Seaport Therapeutics (NASDAQ:SPTX) Given Buy Rating at HC Wainwright - MarketBeat
Seaport Therapeutics, Inc. 2026 Q2 Financials: Forward-Looking Statements, Risks, and Company Highlights - Minichart
Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX - Moomoo
Seaport Therapeutics reports Q2 2026 net loss $62.6M, $427.3M cash; advances GlyphAllo and GlyphAgo - TradingView
Earnings Flash (SPTX) Seaport Therapeutics Posts Q2 Loss $1.78 a Share - marketscreener.com
Seaport Therapeutics, Inc. 2Q 2026: Revenue $0 Net loss $(62.6)M, EPS $(1.78) — 10-Q Summary - TradingView
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - Yahoo Finance
Seaport Therapeutics (SPTX) Earnings Date and Reports 2026 - MarketBeat
Seaport Therapeutics, Inc. Revenue Breakdown – NASDAQ:SPTX - TradingView
SPTX Price Today: Seaport Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Michael Cunyuan Chen Net Worth (2026) - GuruFocus
Seaport Therapeutics, Inc. Revenue Breakdown – BOATS:SPTX - TradingView
Lana Gladstein Net Worth (2026) - GuruFocus
Enterprise value to EBITDA forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Q2 Earnings Forecast for SPTX Issued By HC Wainwright - MarketBeat
Seaport Therapeutics (NASDAQ:SPTX) Stock Rating Upgraded by HC Wainwright - MarketBeat
Seaport Therapeutics stock initiated at buy by H.C. Wainwright - Investing.com Canada
Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress - AOL.com
Wolfe Research Initiates Seaport Therapeutics(SPTX.US) With Hold Rating - Moomoo
Price to earnings forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Price to sales forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
SPTX Forecast — Price Target — Prediction for 2027 - TradingView
Seaport Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPTX) - TradingView
Price to book forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Enterprise value to EBIT forward of Seaport Therapeutics, Inc. – NASDAQ:SPTX - TradingView
Insider Stock Purchases: June 24, 2026 - Moomoo
Seaport Therapeutics, Inc.(NasdaqGS: SPTX) added to S&P TMI Index - marketscreener.com
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Seaport Therapeutics Inc Stock (SPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):